I would just add that the beauty of the new approach we're proposing is that you could attach the studies that Chris is talking about to the licence, so that you would be saying that based on the science and the sound science in the best interests of Canadians, we will issue a licence for a drug. But we want to make sure that we monitor it closely, for whatever reason. If there's something in the science that's telling us that we don't have all the information at this point, but we've made this assessment--and it's always going to be based on science--that the benefits outweigh the risks at this time, but we want to monitor it very closely as it moves forward, right now we can't do that. We would just give it a licence, wait for an adverse event to happen, and then just pull the licence, which is a very blunt instrument.
With this progressive licensing, we could say to the company that they have to carry out this post-market surveillance, they have to submit the studies, they have to reassess the product, and we will be monitoring it very closely. So we would be able to use something that isn't taking the drug off the market, because it does benefit. As long as the profile always remains that the benefit outweighs the risk, then you would continue to have it out in the market.